HOME >> BIOLOGY >> NEWS
Researchers make headway in mystery of migraines

MONTREAL 27 July 2005--Scientists at the MUHC have made progress in understanding what causes migraines. The research, published in the new issue of the Proceedings of National Academy of Sciences (PNAS), reveals how gene mutations known to cause a form of inherited migraine--the kind that cause debilitating headaches and light flashes known as auras--target a cellular process involved in brain cell communication.

"A number of mutations have been shown to result in familial migraines," says Dr. Rhoda Blostein--a medical scientist at the Research Institute of the MUHC, professor in the Department of Medicine and Biochemistry at McGill University, and author of the new study. "Discovering genetic mutations that cause disease is important, but in order to develop treatments we must understand what these mutations do." By engineering several genetic mutations known to cause inherited migraines (type 2), and incorporating them into human cells, Dr. Blostein and her team showed several genotypes damage the operation of a tiny cellular mechanism commonly known as the Sodium Pump (Sodium/Potassium ATPase enzyme).

"Much of what happens in your brain--from memory to basic movement--is the result of the transmission of electrical impulses along nerve cells," says Dr. Blostein. "This is a basic process by which our brain cells communicate." By expelling sodium from the cell, and drawing potassium from outside, the sodium pump maintains a gradient of potassium, which is critical for the propagation of electrical signals along nerve cells. Like an air conditioner in the heat of summer, the sodium pump is a massive energy hog, consuming around 30% of the energy produced by the cell in order to perform this vital cellular process.

Of particular interest in this study is that some mutations cause migraines by reducing sodium pump efficiency--akin to reducing the power supply. "This is the first time that a genetic mutation of the sodium pump has been shown to
'"/>

Contact: Ian Popple
ian.popple@muhc.mcgill.ca
514-843-1560
McGill University
27-Jul-2005


Page: 1 2

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
(Date:6/25/2020)... ... 24, 2020 , ... eClinical Solutions LLC , a ... accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on ... severe COVID-19. This is the first study of an XPO1 inhibitor in patients ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. (“Lumeda”), ... announced the company has entered a license agreement with Roswell Park Comprehensive Cancer ... exclusive rights to Roswell Park intellectual property surrounding a novel medical device and ...
(Date:6/23/2020)... ... 23, 2020 , ... DeCurtis Corporation, the premier provider of ... Fournier has been appointed CEO and President. Founder and former CEO, David DeCurtis, ... “DeCurtis Corporation has been on an incredible journey for the last twenty years, ...
(Date:6/23/2020)... ... 23, 2020 , ... Nobilis Therapeutics, a biopharmaceutical company focused ... an Investigational New Drug application (IND) with the U.S. Food & Drug Administration ... NBTX-001 in patients with panic disorder (PD). , "Adding a PD trial to ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... of a Small Business Innovation Research (SBIR) program funded by the National Institute ... Toxin Detection in the Field”. The project’s goal was to engineer and develop ...
Breaking Biology Technology:
Cached News: